ONDINE BIOMEDICAL INC. (OBI) — Interim financial results for the period ended 30 June 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the ONDINE BIOMEDICAL RESULTS INVESTOR PRESENTATION. Throughout this quarter presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time via the Q and A tab situated at the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received in the meeting itself. However, the company can view the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Nicholas Labelle, president and chief technology officer. Good afternoon, Giselle. Thank you, Alessandro. Hello, and welcome to ONDINE's twenty twenty five mid year results presentation. We're looking forward to telling you about our strong progress, how we've gained momentum in key areas and how we're preparing for what's coming next. As always, before we dive into the presentation, a quick reminder, today's presentation includes forward looking statements, usual uncertainties and risks. And with that noted, let's move on with the presentation. Our vision remains as bold as ever. A world free from untreatable infections. Of course, we're referring to the steady rise of antibiotic resistance, which is a serious threat to health care worldwide. Already more than 200,000 patients have benefited from this technology, proof that the impact is real. Our photo disinfection platform positions us to address this massive unmet global need that is hospital acquired infections often involving antibiotic resistant microbes. And we're just warming up with rapid growth in Canada and now expanding sales into The UK and other countries. As you know, we have ...